Description
PT-141
PT-141 primarily targets melanocortin receptors (MC3R and MC4R) in the brain, which are involved in sexual arousal. By stimulating these receptors, it enhances libido and sexual response independently of nitric oxide pathways, making it effective even for individuals who do not respond to PDE5 inhibitors.
Uses and Benefits
-
Treatment of Sexual Dysfunction
- FDA-approved for HSDD (Hypoactive Sexual Desire Disorder) in premenopausal women under the brand name Vyleesi.
- May be used off-label for erectile dysfunction (ED) and low libido in men.
-
Potential Performance Enhancement
- Increases sexual desire, arousal, and response time in both men and women.
- Can improve spontaneity in sexual activity, unlike PDE5 inhibitors that require timing.
-
Possible Other Uses (Under Research)
- Potential appetite suppression and weight regulation benefits.
- May play a role in pain management and immune system regulation due to melanocortin receptor involvement.
Dosage and Administration
- Typically administered as a subcutaneous injection in the abdomen or thigh.
- Standard dose: 1.75 mg for HSDD in women (self-injected at least 45 minutes before sexual activity).
- Effects can last 6 to 12 hours, with residual effects up to 24-48 hours.
Side Effects
- Common: Nausea, flushing, headache, injection site reactions.
- Less Common: Increased blood pressure, darkening of skin (hyperpigmentation), yawning.
- Rare but Serious: Cardiovascular risks (caution in individuals with hypertension or heart conditions).
Comparison to PDE5 Inhibitors
| Feature | PT-141 (Bremelanotide) | PDE5 Inhibitors (Viagra, Cialis) |
|---|---|---|
| Mode of Action | Central nervous system | Peripheral vascular (blood flow) |
| Effect on Libido | Direct increase in desire | No effect on libido itself |
| Onset Time | 30-60 minutes | 30-60 minutes (Viagra), 15-30 mins (Cialis) |
| Duration | 6-12 hours (sometimes longer) | 4-36 hours (Cialis longest) |
| Administration | Injection | Oral tablet |
| Use for Women | Yes, FDA-approved for HSDD | Not approved |




